Flexion’s Pandemic Rebound: How Zilretta Dropped 80% But Is Still Coming Out Ahead
Executive Summary
The knee osteoarthritis injection was hit hard by COVID-19 restrictions, at first. But CEO Mike Clayman reflected in an interview about how the pandemic experience is helping fuel further growth for Zilretta.
You may also be interested in...
‘Business Unusual’: COVID-19 Brought Commercial Changes To Pharma And It May Stick
The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.
Novartis Broadens VISION On Radioligands
Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge.
Pandemic Perspectives: What’s The New Normal For The Business Of Biopharma?
In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry.